OpenEvidence vs UpToDate (2026)
Both answer the same clinical question at the same moment. The split is what the answer is grounded in and who pays for it. If your failure mode is a fluent answer built on real citations with faulty reasoning behind them, the independent literature documents precisely that in OpenEvidence: accurate citations, interpretive errors. If your failure mode is an authoritative answer inheriting the blind spots of a single editorial tradition, that is UpToDate's structural exposure, and it publishes no evaluation output to bound it. OpenEvidence is free, funded by pharmaceutical and device advertising, and United States only since April 2026. UpToDate is subscription funded, openly priced at the individual tier, and sold in more than thirty countries. Start with UpToDate if oversight design decides it, OpenEvidence if literature breadth and cost do.
- The independent evidence base is deeper here than almost anywhere in this index, and the vendor commissioned none of it. A systematic review following PRISMA covering eleven studies published between 2024 and 2026 found the platform generates evidence supported answers and avoids fabricated citations, performing strongest on structured guideline based questions. UpToDate has no published benchmark or evaluation result of any kind for Expert AI, despite having published a framework for evaluating clinical AI.
- Grounding is breadth, and it is current. More than 300 medical journals plus FDA and CDC sources, under official AI partnerships with the New England Journal of Medicine, with JAMA and its eleven specialty journals, with Cochrane Systematic Reviews and with the NCCN, alongside content agreements across more than a dozen specialty societies. If the question turns on evidence published in the last eighteen months, this is the corpus more likely to hold it.
- Security and compliance disclosure is materially stronger and independently attested. SOC 2 Type II for the Security trust services category verified through a public trust centre, an annual external penetration test, ten named security policies reviewed annually, a vulnerability disclosure programme with a bug bounty, and cloud providers named specifically. This index located no SOC 2, no attestation and no trust centre for UpToDate.
- The oversight architecture is the best of any generative clinical product graded in this index. Every answer opens with a stated assumptions block naming what the system took for granted about the patient, and inline nudges ask the clinician to supply context the system lacks, such as comorbidities or ICU status. It names the gap rather than papering over it. OpenEvidence publishes no abstention behaviour, uncertainty signal or equivalent mechanism.
- No conflict of interest sits between the clinician and the answer, because the reader pays. OpenEvidence is funded by pharmaceutical and medical device advertising, and while its advertising policy states advertisers cannot influence answers, the reverse direction is unpoliced: reporting on its privacy policy describes engagement with particular clinical topics being used to target advertising by specialty and interest. Ads may not shape the answer, but the questions shape the ads.
- It is still available in Europe, and the institutional compliance path is more conventional. OpenEvidence terminated access across the European Union and the United Kingdom at the end of April 2026, citing regulatory uncertainty including the EU AI Act. UpToDate sells in more than thirty countries, though its Expert AI layer is itself bounded to individual subscribers in the United States and Canada, so the contrast is withdrawal against limited rollout.
This comparison is published by AI Health Index, an independent research platform that compares healthcare AI vendors objectively. OpenEvidence and UpToDate are each graded against the same capability taxonomy, from each vendor's own public materials and the regulatory record, under the AI Health Index verification standard. No vendor pays for placement, and no vendor has reviewed this page. How this evidence is graded
Plain facts
| Fact | OpenEvidence | UpToDate |
|---|---|---|
| Primary category | Clinical Reference & Evidence | Clinical Reference & Evidence |
| Founded | 2021 | Not recorded |
| Headquarters | Miami, Florida | Waltham, Massachusetts |
| Website | openevidence.com | wolterskluwer.com |
Side by Side
Each record in one paragraph
Written to be quoted whole. Each paragraph states what the AI Health Index verified about the vendor, with the caveats attached.
OpenEvidence is graded in the AI Health Index as an AI medical search and clinical decision support platform, free to verified United States clinicians and funded by pharmaceutical and medical device advertising. It reports more than 757,000 verified clinician users and roughly 20 million clinical consultations per month as of January 2026, grounds its answers in more than 300 medical journals plus FDA and CDC sources under official partnerships with the New England Journal of Medicine, JAMA and the NCCN, and is the subject of a peer reviewed systematic review of eleven independent evaluations, which found it avoids fabricated citations and performs best on structured guideline based questions. It withdrew from the European Union and the United Kingdom at the end of April 2026, verifies users through the United States National Provider Identifier, and publishes no abstention behaviour or uncertainty mechanism for its answers.
Source: AI Health Index, August 2026
UpToDate is graded in the AI Health Index as the reference clinical decision support product, published by Wolters Kluwer and in market for more than thirty years, with content curated by over 7,600 physician authors and reported use by more than three million clinicians worldwide. Its generative layer, UpToDate Expert AI, draws exclusively on UpToDate's expert authored and peer reviewed corpus and carries the strongest oversight design of any generative clinical product graded in this index: every answer opens with a stated assumptions block naming what the system took for granted about the patient, and inline nudges ask the clinician to supply missing context such as comorbidities or ICU status. It publishes no benchmark or evaluation results for Expert AI, and Expert AI reaches individual subscribers in the United States and Canada while the underlying product sells in more than thirty countries.
Source: AI Health Index, August 2026
Questions buyers ask
Is OpenEvidence better than UpToDate?
Neither is better across the board, and the AI Health Index grades them as different machines answering the same clinical question. OpenEvidence is a free, advertising funded literature engine with the deepest independent evidence base of almost any product in this index: a peer reviewed systematic review covering eleven studies found it generates evidence supported answers and avoids fabricated citations, performing strongest on structured guideline based questions.
UpToDate Expert AI has published no evaluation results at all, but its oversight design is the best the AI Health Index has graded in any generative clinical product, opening every answer with its stated assumptions about the patient and prompting the clinician for context the system lacks. Choose OpenEvidence when literature breadth, recency and cost decide the purchase; choose UpToDate when oversight architecture and institutional trust decide it.
How much do OpenEvidence and UpToDate cost?
OpenEvidence is free to verified United States clinicians and is funded by pharmaceutical and medical device advertising, which means the reader is not the customer. UpToDate is subscription funded, with individual list pricing published openly at several hundred dollars per year depending on tier and professional status, trainee discounts available, and Expert AI included in United States personal subscriptions.
Neither vendor publishes enterprise pricing, which is the tier a health system actually buys; both quote it through sales. Graded by AI Health Index against the same capability axes from each vendor's own published materials and the regulatory record, verified August 14, 2026. No vendor pays for placement.
Can clinicians outside the United States use OpenEvidence?
Not in Europe. OpenEvidence terminated access across the European Union and the United Kingdom at the end of April 2026, citing regulatory uncertainty including the EU Artificial Intelligence Act, and its verification is built around the United States National Provider Identifier, so the product is now United States centred.
UpToDate sells in more than thirty countries, though its Expert AI layer reaches individual subscribers in the United States and Canada, so the contrast is withdrawal against limited rollout. Graded by AI Health Index against the same capability axes from each vendor's own published materials and the regulatory record, verified August 14, 2026. No vendor pays for placement.
Which is safer for clinical decision support?
Safety splits into two different failure modes here, and the AI Health Index assessment names both rather than scoring one winner. The OpenEvidence failure mode is a fluent answer built on real citations with faulty reasoning behind them; the independent literature documents exactly that pattern, accurate citations with interpretive errors on complex cases.
The UpToDate failure mode is an authoritative answer inheriting the blind spots of a single editorial tradition, with no published evaluation output to bound it. UpToDate's stated assumptions block and inline nudges are the strongest oversight mechanism graded in this index, while OpenEvidence publishes no abstention behaviour or uncertainty signal. Neither replaces clinical judgment, and a buyer weighing safety should decide which failure mode their clinicians are better equipped to catch.
Do OpenEvidence and UpToDate integrate with Epic and other EHR systems?
Both reach the point of care, by different routes and at different maturities. OpenEvidence has enterprise deployments embedding the platform inside Epic at named health systems, a newer integration path. UpToDate has been integrated into EHR workflows across thousands of hospitals for decades and draws its drug information from Lexidrug, so its footprint inside existing clinical systems is far larger.
For a health system already standardised on UpToDate, the integration question favours the incumbent; for individual clinicians the products are used mostly through their own apps and sites. Graded by AI Health Index against the same capability axes from each vendor's own published materials and the regulatory record, verified August 14, 2026. No vendor pays for placement.
How does the AI Health Index grade OpenEvidence and UpToDate?
Under the AI Health Index grading framework, every grade records what a buyer can verify from vendor disclosure and independent evidence, and the full axis by axis assessment with notes is published on this page. The retrieval gaps run in different directions: OpenEvidence discloses SOC 2 Type II attestation through a public trust centre, an annual external penetration test and a vulnerability disclosure programme, while UpToDate's HIPAA and security axes are Not Rated because no attestation was located in the material read, not because none exists. Adoption and consultation volume figures on both sides are vendor reported and unaudited, and the index says so rather than repeating them as verified fact.
Related comparisons
Other published head to head assessments involving these vendors or their closest peers. The full set for this category is on the Clinical Reference & Evidence page.
The retrieval gaps on these two records are not symmetric and that shapes the grid. UpToDate's HIPAA and security axes are Not Rated because no attestation was located in the material read, not because none exists: a listed multinational integrated into Epic across thirty countries will hold documentation this index did not find. Its evidence grade carries the same caveat, since an older peer reviewed outcomes literature for the underlying content product exists and was not assessed.
On the OpenEvidence side, the accuracy figures now circulating in competitor marketing, 34 percent for Quick Consult and 41 percent for Deep Consult on subspecialty board questions, come from a November 2025 medRxiv preprint that states plainly it has not been peer reviewed, and on the same dataset eleven large language models scored between 14 and 46 percent, so those numbers sit inside the established band rather than beneath it.
OpenEvidence's own material contradicts itself on protected health information: the security page invites covered entities to transmit it under a Business Associate Agreement while the About page states user inputs are not covered by HIPAA. Neither vendor publishes enterprise pricing, which is the tier a health system actually buys. Adoption, scale and consultation volume figures on both sides are vendor reported and unaudited.